1. Kamanger F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150,2006.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, YuM, Ruhl J, Tatalvich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER cancer statistics review, 1975-2011.National cancer institute, Bethesda, 2014. Https://seer.cancer.glov/archive/csr/1975_2011/,2014.
3. 国立研究開発法人国立がん研究センターがん対策情報センター. がん情報サービス http://gan-joho.jp/professional/index.html Accessed March 14,2019.
4. Japan Society for Head and Neck Cancer Cancer Registry Committee: Report of Head and Neck Cancer Registry of Japan Clinical Statistics of Registered Patients 2013.頭頸部癌 41:1-115,2015.
5. 加藤孝邦、波多野篤、斉藤孝夫. 耳鼻咽喉科・頭頸部外科領域疾患の最新疫学: 頭頸部癌.耳鼻咽喉科・頭頸部外科 85:1076-1083,2013
6. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, Bhatia K, Chen LZ, Fang B, Lisker R. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 88:344-346,1992
7. Matsuo K, Wakai K, Hirose K, Ito H, Saito T, Tajima K. Alcohol dehydrogenase 2 His47Arg polymorphism influences drinking habit independently of aldehyde dehydrogenase 2 Glu487Lys polymorphism: analysis of 2,999 Japanese subjects. Cancer Epidemiol Biomarkers Prev 15:1009-1013,2006
8. IARC:IARC monograhs on the evaluation of the evaluation of carcinogenic risk to humans. Vol 83: Tobacco smoke and involuntary smoking. IARC Press, Lyon, 2004.
9. IARC: IARC monographs on the evaluation of carcinogenic risk humans. Vol 89: Smokeless tobacco and some tobacco-specific N-Nitrosamines. IARC Press, Lyon, 2007.
10. Carey TE, Prince MEP. primer of the Molecular Biology of cancer, 2nd ed, wolters Kluwer Health p139-146,2015
11. Hama T, Tokumaru Y, Fujii M, Yane K, Okami K, Kato K, Masuda M, Mineta H, Nakashima T, Sugasawa M, Sakihama N, Yoshizaki T, Hanazawa T, Kato H, Hirano S, Imanishi Y, Kuratomi Y, Otsuki N, Ota I, Sugimoto T, Suzuki S. Prevalence of human papillomavirus in oropharyngeal cancer: a multicenter study in japan. Oncology 87:173-182,2014
12. 徳丸 裕、平野滋、益田宗幸、菅澤正、中島寅彦、花澤豊行、崎浜敬之、倉富勇一朗、丹生健一、加藤久幸、今西順久、藤井正人、杉本太郎、鈴木真輔、 佐藤雄一郎、家根且有、濱孝憲、志賀清人、峯田周幸、吉崎智一、大上研二太田一郎.中咽頭癌におけるヒト乳頭種ウイルスの関与に関する多施設共同研究.頭頸部癌 37:398-404,2011
13. 人 口 動 態 統 計 （ 厚 生 労 働 省 大 臣 官 房 統 計 情 報部 ） .http://www.mhlw.go.jp/toukei/saikin/hw/jin-kou/geppo/nengai15/index.html Accessed March 14,2019.
14. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576-582,2015
15. Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, Clump DA, Heron DE, Beriwal S. Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer 122: 2021-2030, 2016
16. Agrawal N, Frederick MJ, Pickering CR, Bottegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Winstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelesten B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154- 1157,2011
17. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, Mckenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Sakasena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernander-Lopez JC, Hidalgo-Miranda A, Melendez-Zaigla J, Winckler W, Ardie K, Gabriel SB, Meyerson M, Lander ES Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160,2011
18. Poeta ML, Manola J, Goldwasser MA, Forastere A, Benoit N, Califano JA, Goodwin J, Kenedy D, Sausders J, Westra W, Sidransky D, Koch WN. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552- 2561,2007.
19. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701-713,2009
20. Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, Willian WN, Caulin C, Frederik M, Kimmel M,Myers JN, Lichtarge O. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res 75:1527-1536,2015
21. Zhang B, Wang J, Wang X, Zhu J, Liu J, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, Kinsinger CR, Rivers RC, Rodriguez H, Townsend RR, Elis MJ, Carr SA, Tabb DL, Coffey RJ, Slebos RJ, Liebler DC, NCI CPTAC. Proteogenomic characterization of human colon and rectal cancer. Nature 513: 382-387,2014
22. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13:227-232,2012
23. Hinni ML, Ferlito A, Brandwein-Gensler MS, Takes RP, Silver CE, Westra WH, Seethala RR, Rodrigo JP, Corry J, Bradford CR, Hunt JL, Strojan P, Devaney KO, Gnepp DR, Hartl DM, Kowalski LP, Rinaldo A, Barnes L.Surgical margins in head and neck cancer: A contemporary review. Head Neck 35:1362-1370,2013
24. Petruzzi M, Lucchese A, Baldoni E, Grassi FR, Serpico. Use of Lugol’s iodine in oral cancer diagnosis: an overview. Oral oncology 46:811-813,2010
25. Ismailov S, Rashitov M, Kobayashi M, Shibata N, Kato Y, Omi Y, Iihara M, Okamoto T. Trefoil factor 3 (TFF3) mRNA expression level in follicular thyroid tumors using formalin-fixed, paraffin-embedded (FFPE) blocks. Open Journal of Pathology 3:78– 84,2013
26. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS One 2:e1261,2007.
27. Sánchez-Navarro I, Gámez-Pozo A, González-Barón M, Pinto-Marín A, Hardisson D, López R, Madero R, Cejas P, Mendiola M, Espinosa E, Vara JA. Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques 48:389– 397,2010
28. Mittempergher L, de Ronde JJ, Nieuwland M, Kerkhoven RM, Simon I, Rutgers EJ, Wessels LF, Van't Veer LJ. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 6:e17163,2011
29. Schache AG, Liloglou T, Risk JM, Filia A, Sheard J, Woolgar JA, Heliwell TR, Triantafyllou A, Robinson M, Sloan P, Harvey-Woodworth C, Sisson D, Shaw RJ. Evaluation of human papilloma virus diagnostic testing on oropharyngeal squamous cell carcinoma: sensitivity, specificity and prognostic discrimination. Clin Cancer Res 17:6262-6271,2011
30. D’souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WN, Westra WH, Gillison ML. Case-control study of human papilloma virus and oropharyngeal cancer. N Engl J Med 356:1944-1956,2007
31. Melhem MF, Law JC, el-Ashmawy L, Johnson JT, Landerneau RJ, Srivastava S, Whiteside TL. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 146:1170-1177,1995
32. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781-789,2010
33. Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, Woolgar JA, Helliwell TR, Triantafyllou A, Robinson M, Sloan P, Harvey Woodworth C, Sisson D, Shaw RJ. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17: 6262-6271, 2011
34. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguven-Tan PF, Weatra WH, Chng CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35,2010
35. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A. Teknos TN, Chepeha DB, Prince ME, Tsien CL, D’Silva NJ, Yang K, Kumit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146,2008
36. EI-Naggar AK, Westra WH. P16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 34:459-461, 2012
37. ChungCH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trptti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavairus status as prognostic biomarkers of nonoropharyngeal heas and neck squamous cell carcinoma. J Clin Oncol 32:3930- 3938, 2014
38. Parry D, Bates S, Mann DJ, Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cell correlates with high levels of p16INK4/MTS1 tumor suppressor gene product. EMBO J 14:503-511, 1995
39. Andi T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX. Etiological involvement of oncogenic human papilloma virus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5-13, 1998
40. Heyes DN, Grandis JR, El-Naggar AK. The cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. J Clin Oncol 31 :365s, 2013
41. Zhang W, Edwards A, Fang Z, Flemington EK, Zhang K. Integrative Genomics and Transcriptomics analysis reveals potential mechanisms for favorable prognosis of patients with HPV-positive head and neck carcinomas.Sci Rep 6:24927,2016
42. Tinhofer I, Stenzinger A, Eder T, Konschak R, Niehr F, Endris V, Distel L, Hautmann MG, Mandic R, Stromberger C, Weichert W, Budach V. Targeted next-generation sequencing identifies molecular subgroups in seruamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. Ann Oncol 27:2262- 2268,2016
43. Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther 14:608-619. 2015
44. Zhou G, Liu Z, Myers JN. TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem 117:2682-2692, 2016
45. Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, Catherwood MA, Harikin DP, Salto-Tellez M. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer.Histopathology 65:340-352,2014
46. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih leM, Kurman RJ. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24:1248-1253,2011
47. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 47:600-607,2008
48. Leemans CR, Tiwari R, Nauta JJ, Van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of the neck lymph node metastases as a prognostic factor. Cancer 73:187-190,1994
49. van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel NW, Snow GB, Brakenhoff RH. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 10:3614-3620,2004
50. van Houten VM, Tabor MP, van den Brekel MW, Kummer JA, Denkers F, Dijkstra J, Leemans R, Van der Waal I, Snow GB, Brakenhoff RH. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 198:476-486,2002
51. Looser KG, Shah JP, Strong EW. The significance of “positive” margins in surgically resected epidermoid carcinomas. Head Neck Surg 1:107-111,1978
52. Chen TY, Emrich LJ, Driscoll DL. The clinical significance of pathological findings in surgically resected margins of the primary tumor in head and neck carcinoma. Int J Radiat Oncol Biol Phys 13:833-837,1987
53. Loree TR, Strong EW. Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 160: 410-414,1990
54. Garzino-Demo P, Dell’Acqua A, Dalmasso P, Fasolis M, La Terra Maggiore GM, Ramieri G, Berrone S, Ramipino M, Schena M. Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma. J Craniomaxillofac Surg 34:344-350,2006
55. El-Husseiny G, Kandil A, Jamshed A, Khafaga Y, Saleem M, Allam A, AI-Rajhi N, Ai-Amro A, Rostom AY, Abuzeid M, Otischan A, Flores AD. Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors. Br J Oral Maxillofac Surg 38:193-199,2000
56. Pimenta Amaral TM, Da Silva Freire AR, Carvalho AL, Pinto CA, Kowalski LP. Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of the mouth. Oral Oncol 40:780- 786,2004
57. Weijers M, Snow GB, Bezemer DP, van dr Wal JE, van der Waal I. The status of the deep surgical margins in tongue and floor of mouth squamous cell carcinoma and risk of local recurrence; an analysis of 68 patients. Int J Oral Maxillofac Surg 33:146- 149,2004
58. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, <achtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944,2004
59. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveizer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999-1004,1996
60. Shah JP, Cendon RA, Farr HW, Strong EW. Carcinoma of the oral cavity. factors affecting treatment failure at the primary site and neck. Am J Surg 132:504-507,1976
61. Johnson JT, Barnes EL, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 107: 725-729,1981
62. Feldman M, Fletcher GH. Analysis of the parameters relating to failures above the clavicles in patients treated by postoperative irradiation for squamous cell carcinomas of the oral cavity or oropharynx. Int J Radiat Oncol Biol Phys 8:27-30,1982
63. Mirimanoff R, Wang CC, Doppke KP. Combined surgery and postoperative radiation therapy for advanced laryngeal and hypopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 11:499-504,1985
64. Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, Morrison WH, Weber RS, Garden AS, Frankenthaler RA. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 26: 3-11,1993
論文の公開元へ
